You do seem very passionate. But this does seem to be clutching...

This explanation raises several red flags. In the highly volatile world of biotech investment, even early-phase clinical data like stable disease results can have a material impact on stock prices. For a company to deem this not market-sensitive enough for an ASX release — while choosing to disclose it through a media release and LinkedIn post — is not only concerning, but it also calls into question the integrity of its disclosure practices.

Clinical trial results should be disclosed transparently and fairly to the entire market via ASX, not selectively to those monitoring a company's social media feed. This selective approach undermines market fairness and raises serious questions about the company’s commitment to transparency.

Why This Matters

The collapse of institutional and sophisticated investor support for Chimeric Therapeutics is not just a coincidence — it is a direct consequence of governance failures and regulatory complacency.

In October 2024, Chimeric completed a $5 million capital raise with the backing of institutional, professional, and sophisticated investors. However, by February–March 2025, the company was unable to secure similar support for a follow-on raise.

While the identities of investors in each round have not been publicly disclosed, the sharp decline in demand suggests a significant loss of confidence among sophisticated investors.

Why? Because when companies suppress critical trial data, drip-feed market-sensitive information through LinkedIn posts instead of ASX announcements, and raise capital under the cloud of undisclosed insider information — serious investors start walking away.

No credible investor risks their capital when market rules are treated as optional.

ASIC's silence has not gone unnoticed either.

When regulators turn a blind eye to potential misconduct, they don’t just fail to protect retail investors — they actively embolden bad actors to keep pushing boundaries, distorting markets, and undermining trust.

The message is clear: When enforcement fails, misconduct flourishes.

Retail shareholders are left to pay the price for regulatory neglect.

It’s time for ASIC to stop talking about market integrity — and start defending it.

These are not minor administrative oversights. They are serious governance failures that hurt retail investors, distort market integrity, and undermine confidence in Australia’s public markets.

When directors and companies can selectively release information, delay trial data disclosure, obstruct shareholder rights, and avoid regulatory scrutiny, trust is destroyed.

ASIC has the mandate. ASIC has the evidence. ASIC must now demonstrate that it also has the will to act — because when enforcement is weak, misconduct thrives.

Retail shareholders deserve better.

#ASX #ASIC #ChimericTherapeutics #InsiderTrading #Governance #ShareholderRights #CorporateAccountability #CHM

The information in this article is based solely on publicly available sources and reflects the author's understanding as of the date of publication. To the best of the author's knowledge, no enforcement action has been taken by ASIC or the ASX regarding the matters raised; however, private investigations (if any) have not been publicly disclosed. This article does not constitute financial advice and is intended for informational purposes only.

You do seem very passionate.

But this does seem to be clutching at straws.

Inclusion into ASH can have the requirement that news is not released before the event. I have held several companies that have had to follow that requirement. Not saying thats the case, but maybe everything isnt as sinister as you are making it?